Published in Br J Dermatol on August 25, 2015
Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo. Ann Transl Med (2015) 0.81
Tumour necrosis factor-α antagonists as therapies for vitiligo. Br J Dermatol (2015) 0.75
Recent advances in understanding vitiligo. F1000Res (2016) 0.75
The Fas death factor. Science (1995) 13.81
Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol (2003) 10.29
A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature (1997) 10.14
The pathophysiology of tumor necrosis factors. Annu Rev Immunol (1992) 8.38
Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev (2001) 7.60
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 6.49
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (2002) 6.12
Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature (1994) 5.58
A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell (1988) 5.42
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum (1993) 5.05
Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther (2007) 5.02
TNF-mediated inflammatory disease. J Pathol (2008) 5.00
Etanercept as monotherapy in patients with psoriasis. N Engl J Med (2003) 4.57
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 3.97
Two tumour necrosis factor receptors: structure and function. Trends Cell Biol (1995) 3.67
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum (2003) 3.47
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis (2013) 3.43
Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. J Immunol (1987) 3.41
Chemokines: multiple levels of leukocyte migration control. Trends Immunol (2004) 3.32
TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation (2008) 3.19
Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum (1995) 3.10
Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med (1987) 3.03
Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol (1993) 3.03
Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol (2002) 3.01
Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol (2002) 2.94
Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol (2007) 2.92
Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum (1988) 2.77
TNF receptor subtype signalling: differences and cellular consequences. Cell Signal (2002) 2.57
TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov (2010) 2.17
Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev (2008) 2.13
A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8⁺ T-cell accumulation in the skin. J Invest Dermatol (2012) 2.05
Synergy between interferon-gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kappaB. J Biol Chem (1997) 2.05
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol (2004) 1.66
Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol (2009) 1.62
Interplay between TNF and regulatory T cells in a TNF-driven murine model of arthritis. J Immunol (2011) 1.61
Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol (1999) 1.57
Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res (2012) 1.48
Treatment of psoriasis with adalimumab. Clin Exp Dermatol (2007) 1.48
Interferon-gamma Inhibits Melanogenesis and Induces Apoptosis in Melanocytes: A Pivotal Role of CD8+ Cytotoxic T Lymphocytes in Vitiligo. Acta Derm Venereol (2015) 1.48
CCL22 to Activate Treg Migration and Suppress Depigmentation in Vitiligo. J Invest Dermatol (2015) 1.46
New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res (2002) 1.42
Induction of the chemokine receptor CXCR3 on TCR-stimulated T cells: dependence on the release from persistent TCR-triggering and requirement for IFN-gamma stimulation. Eur J Immunol (2002) 1.42
Cytosolic dsDNA triggers apoptosis and pro-inflammatory cytokine production in normal human melanocytes. Exp Dermatol (2015) 1.42
Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest (2003) 1.41
Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J Clin Invest (2010) 1.40
Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest (2000) 1.39
Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy (2010) 1.35
Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol (1996) 1.35
Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol (2009) 1.34
Interleukins 1 alpha and 6 and tumor necrosis factor-alpha are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J Invest Dermatol (1991) 1.26
Influence of inflammatory mediators and cytokines on human melanocyte function. J Invest Dermatol (1993) 1.25
Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice. J Immunol (2010) 1.24
4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J Invest Dermatol (2005) 1.20
Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. J Invest Dermatol (1993) 1.19
Anti-TNF therapy. Best Pract Res Clin Rheumatol (2011) 1.18
Etanercept (Enbrel): update on therapeutic use. Ann Rheum Dis (2000) 1.13
Vitiligo during Treatment of Crohn's Disease with Adalimumab: Adverse Effect or Co-Occurrence? Case Rep Dermatol (2011) 1.09
Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res (2010) 1.09
Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab. Dermatology (2008) 1.08
Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J Immunol (1998) 1.08
Treatment of generalized vitiligo with anti-TNF-α Agents. J Drugs Dermatol (2012) 1.08
A novel, antigen-presenting function of melanocytes and its possible relationship to hypopigmentary disorders. J Immunol (1993) 1.08
Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev (2004) 1.05
A quantitative increase in regulatory T cells controls development of vitiligo. J Invest Dermatol (2013) 1.05
Modulation of melanocyte intercellular adhesion molecule-1 by immune cytokines. J Invest Dermatol (1990) 1.03
Tumor necrosis factor. J Am Acad Dermatol (1991) 1.01
Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol (2012) 1.01
TNF Receptor 2 and Disease: Autoimmunity and Regenerative Medicine. Front Immunol (2013) 1.01
Genomic structure, induction, and production of TNF-alpha. Immunol Ser (1992) 1.00
Increased tumor necrosis factor alpha (TNF-alpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with nonsegmental vitiligo. Int J Dermatol (2006) 1.00
Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. Arthritis Care Res (Hoboken) (2013) 0.99
Keratinocyte dysfunction in vitiligo epidermis: cytokine microenvironment and correlation to keratinocyte apoptosis. Histol Histopathol (2009) 0.98
Comparative cytokine gene expression in synovial tissue of early rheumatoid arthritis and seronegative spondyloarthropathies. Br J Rheumatol (1997) 0.97
Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum (1996) 0.97
Impaired PI3K/Akt activation-mediated NF-kappaB inactivation under elevated TNF-alpha is more vulnerable to apoptosis in vitiliginous keratinocytes. J Invest Dermatol (2007) 0.95
New-onset vitiligo during long-term, stable infliximab treatment of pityriasis rubra pilaris. J Drugs Dermatol (2013) 0.95
Infliximab-induced vitiligo. Dermatology (2005) 0.94
Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues. Clin Immunol (2011) 0.92
Deterioration of vitiligo and new onset of halo naevi observed in two patients receiving adalimumab. Dermatol Ther (2013) 0.90
Increased interleukin-6 and granulocyte-macrophage colony stimulating factor levels in the sera of patients with non-segmental vitiligo. J Dermatol Sci (2003) 0.90
Clinical features and histological findings are potential indicators of activity in lesions of common vitiligo. Br J Dermatol (2012) 0.89
A patient with psoriasis and vitiligo treated with etanercept. Am J Clin Dermatol (2010) 0.89
Serum concentration of IL-6, IL-2, TNF-α, and IFNγ in Vitiligo patients. Indian J Dermatol (2012) 0.88
Vitiligo in a patient receiving infliximab for refractory ulcerative colitis. Arab J Gastroenterol (2011) 0.88
Increased Tumor Necrosis Factor (TNF)-α and its promoter polymorphisms correlate with disease progression and higher susceptibility towards vitiligo. PLoS One (2012) 0.87
[Cutaneous events during anti-TNF alpha therapy: a prospective observational study of 41 cases]. Ann Dermatol Venereol (2009) 0.83
Vasculitis, vitiligo, thyroiditis, and altered hormone levels after anti-tumor necrosis factor therapy. J Rheumatol (2011) 0.83
TNFα: activator or inhibitor of regulatory T cells? Joint Bone Spine (2011) 0.83
Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) in isolated vitiligo: a genotype-phenotype correlation. Pigment Cell Melanoma Res (2011) 0.81
Involvement of interferon-gamma genetic variants and intercellular adhesion molecule-1 in onset and progression of generalized vitiligo. J Interferon Cytokine Res (2013) 0.81
Why treatments do(n't) work in vitiligo: An autoinflammatory perspective. Autoimmun Rev (2014) 0.81
Tumor necrosis factor-α in vitiligo: direct correlation between tissue levels and clinical parameters. Cutan Ocul Toxicol (2011) 0.81
Vitiligo melanocytes in long-term culture show normal constitutive and cytokine-induced expression of intercellular adhesion molecule-1 and major histocompatibility complex class I and class II molecules. Br J Dermatol (1998) 0.79
Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function. Br J Dermatol (2007) 0.79
Etanercept in the treatment of vitiligo. Dermatology (2007) 0.78
Segmental vitiligo after infliximab use for rheumatoid arthritis--a case report. An Bras Dermatol (2014) 0.78
[Analysis of lymphocyte populations in psoriatic plaques following inhibition of tumor necrosis factor alpha with etanercept]. Actas Dermosifiliogr (2007) 0.78
Tumor necrosis factors blocking agents: analogies and differences. Acta Biomed (2012) 0.78
Secretion of proinflammatory cytokines by normal human melanocytes in response to lipopolysaccharide. Acta Biochim Pol (2011) 0.78